A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Not yet recruiting
Lantheus Medical Imaging
Early Phase 1
2022-11-30
To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer,
HCC, or pancreatic cancer
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Not yet recruiting
M.D. Anderson Cancer Center
Early Phase 1
2022-11-30
To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer,
HCC, or pancreatic cancer
This is a voluntary research study to find out how using technology including advanced
magnetic resonance imaging (MRI) and prostate-specific membrane antigen - positron emission
tomography (PSMA-PET) scan imaging, in addition to combined prostate treatment using
radiation therapy, brachytherapy (internal radiation treatment using small radioactive seeds
placed inside the body) and androgen deprivation therapy (drug therapy to suppress hormones)
can help doctors see, track and predict tumor response to treatment for prostate cancer
patients. Participation in this study will consist of radiation planning and simulation,
magnetic resonance imaging (MRI) and positron emission tomography and computed tomography
scan (PET/CT). One MRI and PSMA PET/CT scan will be done prior to the start of first external
beam radiation therapy (EBRT) fraction. At mid-treatment prior to the second brachytherapy
fraction, an MRI and PSMA PET/CT will be done. A third scan will be performed after 75%
testosterone recovery or 12 months post androgen deprivation therapy (ADT) [whichever comes
first].
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Not yet recruiting
Oregon Health and Science University
Phase 4
2024-05-01
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA)
expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer
(CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA
expression changes tumor staging after therapy initiation. Understanding these effects can
help define the best timing to perform the PSMA positron emission tomography (PET) relative
to the start of therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
